Dr. Bas Trietsch is the Chief Technology Officer and Co-Founder at Mimetas, a company working to contribute to groundbreaking therapies with their screenable, physiologically relevant 3D human disease models. He talks about tissue-relevant models for drug discovery, and how organ-on-a-chip technology can help address scalability and reproducibility.
Featured Products and Resources:
- Register for a live show in New York to discuss BlueRock Therapeutics’ stem cell-derived investigational cell therapy designed to treat patients with Parkinson’s disease.
- Learn about organoid culture from the experts at STEMCELL.
The Stem Cell Science Round Up
CRISPR Screens for Neurodevelopment Genes – Researchers integrated cortical assembloids with CRISPR screening to investigate genes implicated in neurodevelopmental disorders.
Metabolic Reprogramming for Heart Regeneration – Inhibiting fatty acid oxidation in cardiomyocytes stimulates cardiac regeneration in mice.
iPSC-Derived Cardiomyocyte and Endothelial Cell Transplants – hiPSC-derived endothelial cells and cardiomyocytes significantly enhanced graft size and vasculature and improved cardiac function after ischemic reperfusion in non-human primates.
A Bioengineered Trachea-Like Structure – A trachea-like structure composed of cartilage rings and fiber-hydrogel rings boosted survival after transplant into rabbits with a tracheal defect.
Photo Reference: Courtesy of Mimetas